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Abstract
Excitation-contraction coupling involves the faithful conversion of electrical stimuli to mechanical shortening in
striated muscle cells, enabled by the ubiquitous second messenger, calcium. Crucial to this process are ryanodine
receptors (RyRs), the sentinels of massive intracellular calcium stores contained within the sarcoplasmic reticulum.
In response to sarcolemmal depolarization, RyRs release calcium into the cytosol, facilitating mobilization of the
myofilaments and enabling cell contraction. In order for the cells to relax, calcium must be rapidly resequestered or
extruded from the cytosol. The sustainability of this cycle is crucially dependent upon precise regulation of RyRs by
numerous cytosolic metabolites and by proteins within the lumen of the sarcoplasmic reticulum and those directly
associated with the receptors in a macromolecular complex. In addition to providing the majority of the calcium
necessary for contraction of cardiac and skeletal muscle, RyRs act as molecular switchboards that integrate a
multitude of cytosolic signals such as dynamic and steady calcium fluctuations, b-adrenergic stimulation
(phosphorylation), nitrosylation and metabolic states, and transduce these signals to the channel pore to release
appropriate amounts of calcium. Indeed, dysregulation of calcium release via RyRs is associated with life-
threatening diseases in both skeletal and cardiac muscle. In this paper, we briefly review some of the most
outstanding structural and functional attributes of RyRs and their mechanism of regulation. Further, we address
pathogenic RyR dysfunction implicated in cardiovascular disease and skeletal myopathies.
Introduction
In striated and smooth muscle cells, fluctuations in the
intracellular levels of Ca
2+ ions greatly determine the mag-
nitude and duration of contractile force. In cardiac and
skeletal muscle, depolarization of the external membrane
and its invaginations, the T-tubules, elicits swift and mas-
sive Ca
2+ release from the sarcoplasmic reticulum (SR),
which in turn causes ‘flooding’ of the contractile myofila-
ments with Ca
2+ and induction of contraction. This exqui-
sitely coordinated series of events, in which an electrical
stimulus (depolarization) is converted into a mechanical
contraction, is collectively termed ‘excitation-contraction
(EC) coupling’, and it has as central players the voltage-
dependent Ca
2+ channels/dihydropyridine receptors
(DHPRs) as the sarcolemmal voltage sensors, and the Ca
2+
release channels/ryanodine receptors (RyRs) as the SR Ca
2+
release conduits. The structural and functional communi-
cation between the voltage sensor and the RyR dictate the
magnitude of Ca
2+ release from the SR, and thus the force
of contraction. In fact, genetic mutations in either of these
two proteins, or alterations in the environment that
promotes their functional coupling, are known to cause
ventricular arrhythmias, hypercontractures and/or patholo-
gical remodeling of cellular structures. Excellent reviews on
DHPRs have appeared recently [1,2]. In the current review,
we focus on RyRs to discuss their most prominent struc-
tural and functional attributes, and to suggest mechanisms
by which their dysfunction leads to disease.
Structural features of RyRs
RyR isoforms
RyRs are not restricted to striated muscle. This class of
intracellular Ca
2+ release channels is also found in the
endoplasmic reticulum of neurons, exocrine cells, smooth-
muscle cells, epithelial cells, lymphocytes, sea-urchin eggs,
and many others [3]. In all of these cells, RyRs play a central
role in the regulation of the intracellular free Ca
2+ concen-
tration ([Ca
2+]i), whose elevation triggers a cascade of
events that culminates in, for example, neurotransmitter
release, hormone secretion, lymphocyte activation and egg
fertilization. To gain the functional flexibility necessary to
respond to different triggering signals, at least three iso-
forms of RyRs are expressed in mammals, each one
encoded by a distinct gene (ryr1, ryr2 and ryr3), residing on
separate chromosomes. RyR1 is expressed predominantly
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any medium, provided the original work is properly cited.in fast- and slow-twitch skeletal muscle and at lower densi-
ties in cerebellar Purkinje cells, gastric smooth muscle and
B lymphocytes, among others. RyR2 was originally purified
from cardiac muscle (it is the major isoform expressed
there), but is also robustly expressed in neurons, and in
visceral and arterial smooth muscle. RyR3 is the least
understood of the RyR isoforms and seems to play its most
important role during development, although in mature
cells RyR3 is found in diaphragm, epithelial cells, brain, and
smooth muscle [3,4]. There is approximately 65% amino
acid sequence identity between mammalian RyR isoforms
[5]. Most prominent in sequence variation are three regions
of divergence, termed D1, D2 and D3, corresponding to
amino acids 4254 to 4631, 1342 to 1403, and 1872 to 1923
in RyR1, respectively to amino acids 4210 to 4562, 1353 to
1397, and 1852 to 1890 in RyR2, respectively. Because
RyR2 cannot rescue EC coupling in dyspedic myoblasts
(immature muscle cells lacking RyR1) [6], it is likely that
these regions of divergence are responsible for the incapa-
city of rescuing EC coupling with either isoform. Indeed,
D2 has been shown to play a crucial role in establishing
mechanical coupling between RyR1 and the skeletal DHPR
(Cav1.1) [7], but a complete picture of all the structural ele-
ments participating in this mode of EC coupling is still
lacking. D3, by contrast, contains a low-affinity Ca
2+ bind-
ing site [8], but whether this site corresponds to a Ca
2+
inactivation site that operates in vivo has not been
determined.
Molecular architecture of RyRs
With a molecular weight in excess of 2 MDa, RyRs are
indisputably the largest known ion channels. Although
structural study of RyRs has been challenging because of
the channel’s large size, some details of RyR structure
have been obtained through cry-oelectron microscopy
(cryo-EM) [9-13], comparative modeling [14] and
recently, x-ray crystallography of small RyR segments
[15-17]. In electron micrographs, purified RyRs are seen
as quatrefoil or cloverleaf-shaped structures [18-20], or
in volume-filled renderings as mushroom-shaped struc-
tures, with a large (27 × 27 × 12 nm) cytoplasmic assem-
bly and a smaller transmembrane ‘stalk’ spanning
approximately 6.5 nm from the base of the cytoplasmic
region and extending into the SR lumen [21]. The qua-
trefoil structure results from the symmetrical arrange-
ment of four identical subunits of approximately 5,000
amino acids each, thus a single tetrameric channel
encompasses approximately 20,000 amino acids. As if
this structural assemblage was not massive enough, an
RyR in situ serves as a structural scaffold for other pro-
teins and cofactors that add to its discrete bulkiness and
distinctive shape. Indeed, RyRs and associated proteins
where first observed as the ‘foot’ structures that bridge
the gap of approximately 12 nm that separates T-tubule
and SR membranes in cardiac and skeletal muscle [22].
RyR channel protein assembly
The cytoplasmic assembly of RyRs consists of 15 distinct
domains per subunit, including clamp-shaped domains
around the periphery of the channel, connected to
‘handle’ domains surrounding a central cavity [23,24].
Single-particle reconstruction studies indicate that mov-
ing between the closed and open states involves confor-
mational changes in the cytoplasmic assembly and in
the transmembrane domains, which undergo dilation
and constriction around the pore, similar to the iris of a
camera diaphragm [25]. Molecular sieving experiments,
streaming potential experiments, and electrical distance
measurements have suggested a pore approximately 3 Å
wide, with a voltage drop of approximately 10.4 Å in
length [26]. RyR mapping indicates that the pore of the
channel consists of six to eight transmembrane seg-
ments [27]. Recent studies using single-particle three-
dimensional reconstructions of cryo-EM images of
RYR1 at refined resolutions (approximately 10 Å) have
enabled a more detailed picture of the secondary struc-
ture of the channel pore to be pieced together. Samso et
al. [13] suggested that each monomer has at least six
transmembrane a-helices, with four inner helices form-
ing a ‘tepee’ around the central cavity. Further, in the
closed state of the channel, the conformation of the
inner helices of RyR1 resembles that of the closed KcsA
channel. However, Ludtke et al. [28] identified only five
helix-like densities lining the pore of the RyR1 channel,
which, in its closed state, more closely resembles the
structure of open MthK channels rather than closed
KcsA channels. The authors conceded that higher reso-
lution was needed for further clarification.
This incongruity was addressed in a later paper [11], in
which the authors compared the open and closed confor-
mation of the channel to produce three independent 3D
reconstructions, all of which upheld the previous report of
six transmembrane helices. Those authors found that relo-
cation of the ion pathway, in which the inner helices bend
outward and the inner branches separate slightly, is
directly related to an increase of 4 Å in diameter of the
pore during channel gating. Further, by superimposing the
3D reconstructions of the open and closed channel, they
were able to identify structural hinges that correspond to
the previously identified binding sites of regulatory pro-
teins, including calmodulin (CaM) and FK506 (tacroli-
mus)-binding protein (FKBP)12. Thus, they suggested that
the hinges may be the mechanism by which the binding of
a small effector is transduced to the pore region.
Two studies have recently solved high-resolution crys-
tal structures (2.5 Å) of portions of the N-terminal region
of the skeletal RyR (RyR1) associated with pathogenic
mutations. The first study crystallized the N-terminal 210
residues, which were found to adopt a b-trefoil fold, simi-
lar to a suppressor domain of inositol trisphosphate
Capes et al. Skeletal Muscle 2011, 1:18
http://www.skeletalmusclejournal.com/content/1/1/18
Page 2 of 13receptors (IP3Rs) [15]. The disease mutations investigated
in this study clustered in a region within a newly identi-
fied domain, highlighting its importance in channel regu-
lation. The authors proposed that the b-trefoil fold, like
the analogous structure in IP3Rs, may couple to the
C-terminal channel domain to form a suppressor/cou-
pling domain. The second study crystallized a larger con-
struct, comprising N-terminal residues 1 to 559 [17].
This region folds into three distinct domains (arbitrarily
termed A, B and C) per monomer (Figure 1), forming a
vestibule around the pore of the channel. Fifty pathogenic
RyR mutations have been mapped to this region, grouped
on the basis of their proposed effect on channel function.
Six of the mutations are buried deep within the domains,
most probably causing protein misfolding rather than
faulty interaction with channel modulators. Significantly,
most mutations were mapped to inter-domain and inter-
subunit interfaces, thus suggesting that RyR gating is
allosterically coupled to the movement of the A, B and C
domains, and agreeing well with the hypothesis proposed
by Ikemoto et al. [29-31] that disruption of any of the
inter-domain interfaces by disease-associated mutations
may destabilize closed states, increasing the probability of
the channel opening.
The RyR macromolecular complex
As mentioned above, RyRs are often complexed with
several accessory proteins, forming an intricate multi-
protein array [32,33]. The best known RyR-interacting
proteins are CaM, which tonically inhibits RyR2 activity
and produces biphasic effects on RyR1 [34,35]; FKBP12
and FKBP12.6, which stabilize RyR1 and RyR2 closures
[36-38]; and the ternary complex triadin-junctin-calse-
questrin, which ‘senses’ luminal Ca
2+ content and
modulates RyR activity by acting either as a Ca
2+ reser-
voir or as a direct channel ligand [39-47]. More recently,
RyR2 has been found to hold anchoring sites for protein
kinase (PK)A, protein phosphatase (PP)1, the cAMP-
specific phosphodiesterase (PDE)4D3 and Ca
2+/calmo-
dulin-dependent protein kinase (CaMK)II [37,48],
emphasizing the importance of RyR2 regulation by
phosphorylation [32]. In cardiac cells, sorcin exerts pro-
tein-protein interactions with the RyR and inhibits Ca
2+
release in a Ca
2+-dependent manner [49,50].
The binding sites of several regulatory proteins have
been mapped near the ‘clamp’ region of the channels,
encompassing subdomains 5 to 10, an apparent hot-spot
for allosteric modulation. Phosphorylation sites for CaM-
KII and PKA, including Ser2808 and Ser2030, occur in dif-
ferent subdomains within this region [51,52]. Muscular A
kinase anchoring protein (mAKAP) is believed to bind to
RyRs via leucine zippers at residues 3003 to 3039, tether-
ing PKA close to these phosphorylation sites [32]. Another
scaffolding protein, Homer, purportedly interacts with
RyRs via the clamp domain, where it brings Ca
2+ signaling
proteins in close proximity to their respective binding
sites, and may facilitate crosstalk between RyRs and pro-
teins in the surface membrane, such as DHPRs and
b-adrenergic receptors [53-55].
CaM, both in its Ca
2+-bound (Ca
2+-CaM) and
unbound forms (apoCaM), reportedly binds in a cleft
between the ‘clamp’ and ‘handle’ regions [56]. This cleft
occurs between domains 3 and 7 on a portion of the
cytoplasmic assembly of the channel facing the SR,
about 10 nm from the pore [57]. From their cryo-EM
studies, Samso and Wagenknecht [57,58] proposed a
model in which CaM transitions between a distinct, but
Figure 1 Crystallized structure of rabbit ryanodine receptor (RyR)1 for amino acid residues 1-559. This RyR1 segment folds into three
distinct domains, forming a vestibule around the four-fold symmetry axis: domain A (blue; 1-205), domain B (green; 206-394) and domain C (red;
395-532). (A) Cytoplasmic view; (B) close-up lateral view from the four-fold symmetry axis, (C) Docking of domain A alone (blue) or domain BC
alone (red) yields a near-perfect superposition on the docking position for ABC (grey). Adapted from Tung, et al. [17].
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([Ca
2+]i) fluctuates. According to this model, as apoCaM
binds Ca
2+ ions, it loses affinity for the apoCaM site and
translocates to the nearby Ca
2+-CaM site. The CaM
binding sites identified by these studies was corrobo-
rated by a Förster resonance energy transfer (FRET)-
based approach, which identified a CaM target helix
that spanned residues 3614 to 3643. However, [Ca
2+]-
dependent translocation of CaM between adjacent or
overlapping sites could not be detected by FRET, indi-
cating that any such movements must be subtle. The
authors pointed out that such structural rearrangements
could also be explained by changes in the interaction of
CaM with the RyR target sequence or by rotation of
CaM around its major axis [59].
Collins originally reported that a 12-kDa immunophilin
(FKBP12) copurified with RyR1 [60]. Jayaraman et al.
later reported that FKBP12.0 binds to RyR1 with a stoi-
chiometry of one molecule per tetrameric channel [61].
Experimental techniques similar to those described above
have shown that the binding site of FKBP12 also occurs
in the clamp region of the channels; however, there is
some controversy about the exact amino acid region(s)
responsible for this interaction. For RyR1 and RyR3, a
valyl-prolyl motif (amino acid residues 2461 and 2462 in
RyR1) seems to berequired for binding of FKBP12/
FKBP12.6 [62,63]. For RyR2, a variant of this motif (iso-
leucyl-prolyl sequence 2427 and 2428, respectively) has
been implicated in binding FKBP12.6 [37]. However,
Masumiya et al. reported that mutation of Ile-2427 or
Pro-2428 does not alter FKBP12.6 binding [64], and
further, that the RyR2 polypeptide fragment encompass-
ing residues 1 to 1855 is sufficient for binding of
FKBP12.6 [65]. Zhang et al. also found that other regions
of RyR2 contribute to FKBP12.6 binding [66]. As with
CaM, Wagenknecht and colleagues [57] used 3D recon-
structions of cryo-EM images of purified RyRs complexed
with FKBP12 to investigate the site of the interaction,
which was identified on the opposite side of domain 3
f r o mC a M ,a b o u t1 2n mf r o mt h ep o r e .Al a t e rs t u d y
compared 3D reconstructions of native and FKBP12-
stripped RyR1, identifying two surfaces of interaction
between FKBP12 and RyR1: a portion of the b-sheet of
FKBP12 interacts with domain 9 of RyR1 and the inter-
section of domains 3, 5 and 9, w h i l el o o p8 7t o9 0i n t e r -
acts with domain 3 of RyR1 [12].
Functional regulation of ryanodine receptors
In cardiac muscle, a small influx of external Ca
2+ (ICa)
through DHPRs (Cav2.1) binds to and opens RyR2,
releasing a larger amount of Ca
2+ from the SR. This pro-
cess, known as Ca
2+-induced Ca
2+ release (CICR [67,68]),
occurs in diads, which are specialized regions in which a
segment of a T-tubule seems to be continuous with a
semi-spherical extension of the SR [22]. CICR amplifies
the incoming Ca
2+ signal approximately 10 to 20 times,
and is therefore the major component of the intracellular
Ca
2+ transient that induces contraction. In skeletal mus-
cle, ICa is not required for contraction [69]. Instead,
mechanical coupling between DHPRs (Cav1.1) and RyR1
(direct or facilitated by intermediary proteins) triggers
Ca
2+ release from the SR immediately after sarcolemmal
depolarization [70,71]. At the triads, where a segment of
one T-tubule seems to be continuous with two SR evagi-
nations, not all RyRs are closely apposed to DHPRs;
nearly half of RyRs remain DHPR-free and are therefore
presumed to be activated by Ca
2+ release from neighbor-
ing RyRs, effectively amplifying the Ca
2+ signal [72].
Thus, common subcellular structures participate in EC
coupling, but different processes link membrane depolar-
ization to Ca
2+ release in cardiac and skeletal muscle. In
this section, we review some of the most prominent regu-
lators of RyR1 and RyR2 and their effect in Ca
2+ release
in skeletal and cardiac muscle.
Ca
2+ regulation
All three RyR isoforms harbor both activating and inacti-
vating Ca
2+ binding sites. Regardless of some differences
(noted below), the Ca
2+ affinity for those sites is roughly
similar for all RyRs. Thus, Ca
2+ plays a crucial role in the
modulation of RyR activity, even in skeletal muscle [72].
T h eR y Ri saC a
2+-gated channel, hence, functional
assays that measure its activity ([
3H]ryanodine binding,
reconstitution in lipid bilayers, Ca
2+ sparks) require a cri-
tical [Ca
2+] in the medium to maintain the channel in its
open state. However, despite the fact that RyRs in situ
normally encounter fast and transient changes in [Ca
2+],
most of the functional characterizations of single RyR
have been obtained under the continuous presence of a
critical [Ca
2+], that is, under steady-state conditions.
How similar is this characterization to that obtained
under a transient application of [Ca
2+]? Fabiato, in his
classic studies delineating CICR [67,68], found that the
amount of Ca
2+ release was strongly dependent on the
velocity of the Ca
2+ pulse ((d[Ca
2+]/dt) applied to
skinned cardiac fibers. In light of these data, it is surpris-
ing that few studies have addressed the importance of
dynamic fluctuations of Ca
2+ on RyR kinetics. Three such
studies have revealed that a fast Ca
2+ stimulus elicits only
a transient increase in the Po of RyRs; however, if Ca
2+ is
applied rapidly but sustained for long periods, RyR Po
will ‘relax’ to a new steady-state that follows a bell-shaped
curve as a function of the magnitude of Ca
2+ stimulus.
Thus, Po-[Ca
2+] curves of greater magnitude emerge
from titration of RyR activity with fast, calibrated Ca
2+
pulses than those obtained under similar but steady
applications of Ca
2+ (Figure 2) [73-75]. The implication
of these findings is that there are components of RyR
activity that remain undetected in most of the assays
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explain seemingly discrepant results, as in the case of
RyR phosphorylation (see below).
Under steady-state conditions, Ca
2+ concentrations in
the range of approximately 100 nmol/l to approximately
10 μm/l activate all three RyR isoforms [76-78]. The acti-
vation curve is sigmoidal, but the exact Hill number
(cooperativity) and the plateau (maximal activation)
depend greatly on the presence of other cytosolic ligands.
Higher concentrations of Ca
2+ in the range of 100 μmol/l
to approximately 10 mmol/l also inactivate the three RyR
isoforms, although there is considerable RyR heterogeneity
in this process [79,80]. In general, Ca
2+-dependent inacti-
vation is most prominent in RyR1 and less important in
RyR2 and RyR3 [26]. In fact, complete Ca
2+-dependent
inactivation in isolated RyR2 channels occurs at such high
[Ca
2+] (>10 mmol/l) that its physiological relevance is
questionable [58,76]. The agonist effect of ATP and the
inhibitory action of Mg
2+ greatly influence the kinetics of
calcium-dependent activation and inactivation [74], but
the concentration of these two ligands is not expected to
change dramatically over a short period or on a beat-to-
beat basis, thus they may be considered rather as tonic
modulators of RyRs whose influence becomes relevant
under periods of intense muscle activity or in precarious
metabolic states. Given the greater sensitivity of RyR1 to
Ca
2+-dependent inactivation, it is not surprising that Mg
2+
also exerts a more powerful inhibition on the RyR1 iso-
form [74,81], with Mg
2+ apparently binding to both Ca
2+
activation and inactivation sites, attenuating the former
and intensifying the latter.
Recently, regulation of RyRs by luminal (intra-SR) Ca
2+
has been proposed as a critical control mechanism of Ca
2+
release, especially in cardiac cells. The crucial observation
is that, beyond a certain threshold, small changes in SR
Ca
2+ load result in far greater increases in Ca
2+ release,
with the relationship described as an inverse hyperbole
with high degree of cooperativity [82,83]. Direct Ca
2+
binding to sites available only from inside the SR [84], acti-
vation of cytosolic sites by the Ca
2+ ions being permeated
by the channel (’feed-through’ mechanism [85]), and most
notably, regulation by the junctin-triadin-calsequestrin
ternary complex (for example, [39-47]) remain as the lead-
ing candidate mechanisms effecting luminal Ca
2+ regula-
tion of RyRs, although it has been difficult to dissect out
the specific contribution of each of these phenomena.
RyR phosphorylation
RyRs are structural scaffolds for important kinases and
phosphatases [32], and in the heart, RyR2 is one of the
first proteins to undergo phosphorylation during b-adre-
nergic stimulation [86-88]. However, the functional effect
of RyR phosphorylation is unclear and remains the subject
of intense debate. All potential functional outcomes have
been attributed to RyR phosphorylation. On one hand, Li
et al. [89] found that PKA phosphorylation of RyR2 has
little functional relevance for diastolic Ca
2+ release if SR
Ca
2+ levels remain constant. On the other hand, other
groups have suggested that PKA phosphorylation of RyR2
is so essential to intracellular Ca
2+ homeostasis that
derangement of this process may be the basis for heart
failure (HF) [37,90] and catecholaminergic polymorphic
ventricular tachycardia (CPVT) episodes [91]. Between
these two extremes, other results, mainly from in vitro
experiments, imply that PKA phosphorylation increases
[86,92], decreases [74,93] or has no effect [94] on RyR2
activity.
Several factors preclude an easy interpretation of phos-
phorylation results. First, RyRs contain multiple phos-
phorylation sites that, depending on their phospho-state,
may attenuate or synergize the effect of the other sites, or
may require prior phosphorylation to activate the whole
protein. To date, three phosphorylation sites have been
Figure 2 Modulation of ryanodine receptors (RyRs) by Ca
2+.( A)
Ensemble currents of single RyR2 show the effect of fast Ca
2+
pulses on the Po of a non-phosphorylated channel (’control’) or the
same channel after phosphorylation with the catalytic subunit of
protein kinase A (’+PKA’). Laser photolysis of ‘caged Ca
2+’ (o-
nitrophenyl EGTA, tetrapotassium salt; NP-EGTA) increased [Ca
2+]
from 0.1 to 10 μmol/l at the point labeled as ‘Ca
2+ pulse’ (modified
from [51]. (B) Ca
2+-Po curves of RyR1 and RyR2. Channel activity was
measured at the indicated stationary concentrations of Ca
2+ (’RyR1’
and ‘RyR2 steady-state’) and right after a fast Ca
2+ pulse, as in (A)
(’RyR2 (peak Po)’) (unpublished results) (see text for details).
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first identified by Witcher et al. [86] as a CaMKII site,
and later, Wehrens et al. suggested it as the only PKA
site [95], even though RyR2 from mice with genetic abla-
tion of this site may still be phosphorylated by PKA [88].
Ser2815 and Ser2030 seem to be exclusively phosphory-
lated by CaMKII [96] and PKA [97], respectively. Second,
as mentioned above, RyR activity is strongly dependent
on the speed of Ca
2+ application, which in turn may
greatly influence the overall effect of phosphorylation.
For example, PKA phosphorylation of isolated RyR2
increases a transient component of activity (peak activa-
tion) but accelerates the rate of adaptation to a lower
steady-state level of activity [74,88]. In cellular settings,
this effect would translate into greater and faster rates of
Ca
2+ release in response to a given amount of Ca
2+ entry.
Elegant experiments in which SR Ca
2+ load and ICa were
kept constant showed that b-adrenergic stimulation of
ventricular myocytes accelerates the rate of Ca
2+ release
and has little effect on the magnitude of the [Ca
2+]i
transient [98]. Similarly, experiments in rat and mouse
skeletal muscle fibers showed little or no effect of b-adre-
nergic stimulation on the macroscopic Ca
2+ transients
[99]. A recent paper suggested that differences in the
redox state of RyR could account for some the discrepan-
cies seen [100]. Although appealing, this hypothesis still
needs to be corroborated.
CaM
CaM regulates RyR activity both directly as a ligand, and
indirectly as a cofactor for CaMKII. CaM binding to
RyR1 increases channel activity at low [Ca
2+], and
decreases activity at high [Ca
2+][ 3 5 ] .N e v e r t h e l e s s ,a t
the cellular level, this fine modulation might be negligi-
ble compared with the effect of other RyR regulators
such as DHPR and calcium [101]. In skeletal muscle
cells, CaM is proposed to protect RyR1 from oxidative
stress and also work as an oxidative stress sensor (see
below). RyR1 nitrosylation decreases CaM binding and
increases channel activity [102]. The physiological
importance of this mechanism is not clear, but it has
been related to pathological processes [56]. In single
RyR2 channels, only inhibitory effects by CaM have
been shown [26]. CaM binding to both RyR1 and RyR2
can also be regulated by S100A1, a calcium-activated
protein that competes with CaM for the RyR binding
site [103-105]. Although the physiological beat-to-beat
significance of this interaction is not yet clear, its
chronic deregulation potentially plays a role in HF
[106,107]. A recent study suggested that PKA phosphor-
ylation decreases CaM binding, which would subse-
quently increase channel activity [108].
Oxidative stress
Oxidative modifications of thiol residues in free
cysteines, such as S-nitrosylation, S-glutathionylation
and disulfide oxidation, can modulate RyR1 and RyR2
[109-111]. The functional response of RyR may vary
depending on the cysteine residue being modified and
the type of oxidative species that targets it [110,112]. In
addition, oxidative modifications can also affect the
binding of accessory proteins. For instance, most data
suggests that single RyR1 exposure to nitric oxide (NO)
increases channel activity [102]. In skeletal muscle
fibers, this effect is more evident in the presence of
CaM, suggesting that s-nitrosylation of some residues
produces CaM detachment and therefore reversal of the
inhibitory effect of CaM over RyR [56]. Whether NO
directly regulates RyR2 seems likely, but it is not com-
pletely clear. The NO donor
S-nitroso-N-acetyl penicillamine (SNAP), which targets
several EC-coupling proteins, increases inotropy of car-
diac myocytes at low concentrations, but decreases it at
high concentrations [113,114]. It has been proposed that
reduced glutathione (GSH) could quickly react with and
scavenge NO in cardiac cells [111]. Under these circum-
stances, nitroso-GS or other small nitrosylated molecules
would be responsible for RyR oxidation [111]. It is also
possible that the close proximity of nitric oxide synthase
(NOS)-3, xanthine oxidase and RyR2 in cardiac caveolae
creates a microenvironment capable of directly nitrosy-
lating RyR2 [114], although in physiological conditions
the main targets of NOS seem to be other EC-coupling
proteins [115].
RyR dysfunctions
In this section, we describe the role of RyR dysfunction
in the generation of genetic and acquired diseases
afflicting skeletal and cardiac muscle.
Malignant hyperthermia
Mutations in RYR1, the gene encoding the skeletal isoform
of RyRs, are associated with malignant hyperthermia
(MH), a pharmacogenetic disease triggered by inhalational
anesthetics or depolarizing muscle relaxants [116,117]. SR
Ca
2+ ’leak’ or excessive Ca
2+ mobilization from the SR due
to hyperactivity of RyR1 (especially at rest) seems to be
the underlying mechanism for this syndrome [118],
although increased resting [Ca
2+]i nh u m a nm u s c l eh a s
yet to be categorically demonstrated [119]. MH episodes
are rare (approximately 1 in 10,000 surgeries [120]), but in
their severest clinical presentation, susceptible individuals
anesthetized with halothane or other volatile anesthetics
suddenly develop muscle rigidity, hyperkalemia, arrhyth-
mias, respiratory and metabolic acidosis, and an alarming
increase in body temperature. Fulminant death inexorably
follows unless body temperature is lowered and the exces-
sive SR Ca
2+ leak is prevented by dantrolene sodium,
which presumably blocks RyR1, but not RyR2 [121]. More
than 100 different point mutations in human RYR1 have
been identified as potential causes of this syndrome;
Capes et al. Skeletal Muscle 2011, 1:18
http://www.skeletalmusclejournal.com/content/1/1/18
Page 6 of 13however, mutations in other genes, particularly in the a1
subunit of the skeletal DHPR, have also been reported to
generate MH episodes [122]. This syndrome therefore
emphasizes the central role that RyRs and DHPRs play in
EC coupling. Interestingly, the great majority of RYR1
mutations seem to be clustered in three ‘hot spots’,
namely, near the N-terminal (Cys
35-Arg
614), the central
(Asp
2129-Arg
2458) and near the C-terminal (Ile
3916-Ala
4942)
domains of the channel, a clustering that is repeated in an
analogous RyR2-associated syndrome [123] (see below).
Porcine stress syndrome (PSS), which also results from
point mutations of RYR1 (most often R615C) [124], is a
similar MH syndrome, but with a wider array of trigger-
ing events (e.g. exercise, parturition, overcrowding). Sus-
ceptible pigs have been invaluable models to elucidate
the molecular basis of MH in humans. Caffeine, which
sensitizes RyR1 to Ca
2+, elicits contractures of muscle
strips of MH pigs at a lower dose than that required in
control muscle. Caffeine hypersensitivity is also seen in
human MH [125], and constitutes the basis for a clinical
test of susceptibility. The bell-shaped Ca
2+-dependence
of [
3H]ryanodine binding of MH-susceptible pigs is
wider than that of normal pigs, suggesting greater sensi-
tivity of RyR1 to Ca
2+ activation and increased resis-
tance to Ca
2+ inactivation [77]. At the single channel
level, RyR1s from MH-susceptible pigs exhibit similar
conductance to ‘normal’ RyR1s, but they display longer
mean open time and require higher [Ca
2+] for inactiva-
tion. All these findings point to greater Ca
2+ mobiliza-
tion from RyR1-controlled pathways during resting and
contracting periods, with the resultant overflowing of
cytosolic compartments with Ca
2+, and the ignition of
multiple signaling mechanisms. Heat seems to stem
from the rampant hydrolysis of ATP by the SR Ca
2+
pump and other active Ca
2+ transporters trying to rees-
tablish Ca
2+ homeostasis. However, the pathway to MH-
associated heat production may be much more complex,
as shown by the finding that MH mutations cause not
only Ca
2+ dysregulation, but also an increased release of
cytokines (for example, interleukin 6). In sufficiently
large quantities, these cytokines can be pyrogenic [126].
Central core disease
Central core disease (CCD) is another autosomal-domi-
nant myopathy resulting from mutations in RYR1
[127,128]. Although some patients with MH may show
clinical myopathies before an MH episode, histopathologi-
cal lesions characterized by pale staining of the central
area of muscle fibers are necessary to diagnose CCD.
Non-progressive muscle weakness, hypotonia and motor
deficiencies are present in most, but not all, patients with
CCD [129]. Type 1 skeletal muscle fibers are preferentially
affected, with central areas lacking mitochondria and their
oxidative enzymes, thus staining poorly with basophilic
dyes [130]. The cause for the disappearance of central
mitochondria is unknown. A potential explanation is that
the RYR1 mutation, as in MH, causes excessive Ca
2+ leak.
In the periphery of the fiber, Ca
2+-extrusion mechanisms
would be sufficient to remove the excess Ca
2+,b u tt h e
central areas would remain vulnerable to local Ca
2+ gradi-
ents. Central mitochondria would, therefore, ‘swallow’
greater amounts of Ca
2+ than they could handle, leading
to swelling and death [131].
An alternative model for core formation has been pro-
posed, based on studies using a knock-in mouse heterozy-
gously expressing a leaky-channel mutation in the RyR1
N-terminal region [118,132-135]. According to this
model, Ca
2+ leak in the SR triggers the release of reactive
oxygen and nitrogen species (ROS/RNS), causing RYR1
S-nitrosylation and glutathionylation, modifications that
further enhance SR Ca
2+ leak and RyR heat sensitivity.
The authors correlated the resulting cascade of deteriora-
tion with the formation of cores that progress through a
series of histopathologically distinct stages as the mice
age. They proposed that oxidative damage, Ca
2+-depen-
dent proteolysis, and extreme stretching of the myofila-
ments due to prolonged contracture in the presence of
unsequestered Ca
2+ may all contribute to the progression
of the disease. Importantly, these mice are prone to fulmi-
nant MH-like responses to heat challenge and halothane
exposure [118,135].
An entirely different mechanism for the muscle weak-
ness associated with CCD was revealed in recent studies
using a mouse knock-in model expressing a heterozygous
mutation in the RyR1 ion pore [132]. Muscle fibers from
these mice exhibited reduced maximal twitch contraction,
slowed rate of force development [136] and reduced global
Ca
2+ transients [137]. Adult mice displayed weakened
upper body and grip strength [138]. These results were
attributed to reduced and slowed RYR1 Ca
2+ release, with-
out change in either SR Ca
2+ content or RyR1 sensitivity
to activation by voltage or caffeine [138]; this pathway to
CCD-associated muscle weakness is known as EC uncou-
pling [132]. Unlike the leaky-channel knock-ins, these
mice were not prone to developing MH-like symptoms.
Surprisingly, the same mutation produced dramatically
different phenotypes in different strains of mice, experi-
mental approaches, and expression systems [136-138].
Similarly, identical RYR1 mutations cause MH in some
human patients and CCD in others. The mechanism(s)
that leads to the different phenotypes remains a mystery.
Very interesting, however, is the observation that patients
with MH who lack clinical myopathies are more likely to
have mutations at the N-terminus of RYR1,w h e r e a s
those with clinical myopathies are likely to have muta-
tions at the C-terminus [128]. Although these observa-
tions seem to suggest that mutation mapping could
provide an attractively simple predictor of phenotype,
this notion probably oversimplifies the complexity of the
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function of the severity of Ca
2+ leakage, as the studies
discussed above have shown that both C-terminal and N-
terminal mutations are capable of producing this type of
RyR1 dysfunction.
CPVT
CPVT is an autosomal-dominant inherited cardiac disease
characterized by exercise- or stress-induced tachyarrhyth-
mia episodes in the absence of apparent structural heart
disease or prolonged QT interval [139,140]. The disease is
rare but very malignant, often presenting for the first time
in childhood and adolescence as syncopal events and/or
sudden cardiac arrest. Multiple electrocardiographic irre-
gularities (polymorphic) are simultaneously present in
patients with this syndrome. More than 70 different muta-
tions in RYR2, the gene encoding the cardiac isoform of
RyRs, have been associated with CPVT [141], which is
characterized by: a) more than two types of ventricular
tachycardia morphologies, b) absence of underlying
organic heart disease and c) absence of primary electrical
disease (long QT, Brugada syndrome) [142]. CPVT usually
occurs during intense exercise or acute emotional stress,
and may lead to sudden cardiac death. As in MH, exces-
sive Ca
2+ release from the SR, especially during diastole,
seems to be the underlying mechanism that gives rise to
the VT [143,144]. Enhanced diastolic Ca
2+ leak may over-
load the Na
+/Ca
2+ exchanger, which generates an inward
current as it extrudes the released Ca
2+. The inward cur-
rent, in turn, gradually depolarizes the cell to threshold,
favoring delayed after depolarizations (DADs) [145]. Dur-
ing depolarization, lack of Ca
2+-dependent inactivation
of ICa due to previous depletion of the SR leads to higher
Ca
2+ entry and reloading of the SR, which triggers another
DAD in the next beat. Successive repetition of this altered
Ca
2+ cycle could result in paroxysmal tachycardia and
arrhythmias even if only a few foci of ventricular cells are
involved.
Although this hypothetical scheme logically relates
RyR2 dysfunction with VT, it is unclear exactly what
mechanism induces a group of apparently normal RyR2s
to behave aberrantly and to generate sudden tachycar-
dia. Because infusion of catecholamines also triggers
CPVT, it is likely that activation of the b-adrenergic sys-
tem plays an important role. In this regard, it has been
suggested that phosphorylation of RyR2 by PKA, the
kinase linking b1-adrenergic receptor activation to cellu-
lar effects, dissociates FKBP12.6 [37,90,91,146]), an
accessory protein that presumably stabilizes RyR2 in the
closed state. Phosphorylation of a mutant RyR2 would
therefore remove a stabilizer from a channel on the
verge of dysfunction, and would cause the pathogenic
events described above. However, several studies have
not found any evidence of FKBP12.6 dissociation in
CPVT mutation-carrying RyR2 [147,148]. Thus,
structural alterations of the RyR2 channel complex seem
to be more important than dysregulation by accessory
factors in the pathogenesis of CPVT. Consistent with
this notion is the fact that CPVT-associated mutations
of RYR2 occur in domains corresponding exactly to
mutation-containing domains that give rise to MH
[123,141]. Although some of these mutations are close
to the apparent FKBP12.x-binding domain, the great
majority are not. Recent studies point to a predominant
role of Purkinje cells in the genesis of ventricular
arrhythmias [149-151]. Whatever the triggering mechan-
ism, SR Ca
2+ load and release seem to be crucial,
because mutations in CSQ2, the gene encoding cardiac
calsequestrin, an intraluminal Ca
2+ buffering protein
that regulates RyR2 activity, also generate CPVT [152].
Accordingly, a prominent hypothesis, championed
mainly by Chen and collaborators, proposes that cardiac
myocytes have a threshold SR Ca
2+ load for spontaneous
Ca
2+ release, and that CPVT-associated mutations
decrease the sensitivity to luminal Ca
2+ (that is, decrease
the threshold) [143,153]. Thus, during b-adrenergic sti-
mulation, when SR Ca
2+ load increases as a result of
enhanced Ca
2+ entry and uptake, CPVT mutant chan-
nels reach their threshold and generate spontaneous
Ca
2+-release waves, creating a substrate favorable for
Ca
2+-dependent arrhythmias. Alternatively, CPVT-
related mutations could increase the SR load, making
it easier to reach the threshold upon adrenergic stimula-
tion [154].
HF
HF is a multifactorial syndrome characterized by contrac-
tile dysfunction and pathological myocardial remodeling.
There is growing consensus that Ca
2+ mishandling in HF
leads to altered gene transcription, resulting in maladap-
tive structural transformations (cardiac hypertrophy and
then wall thinning) that eventually hamper basic cardiac
function [155]. As with the genetic RyR dysfunctions dis-
cussed above, an enhanced diastolic Ca
2+ leak seems to be
central in the pathogenesis of some forms of HF [156].
According to a prominent hypothesis spearheaded by
Marx et al. [37], increased catecholamine levels in patients
with HF activate cAMP-dependent PKA by binding to
b1-adrenergic receptors. PKA, in turn, phosphorylates
RyR2-Ser2808 and dissociates FKBP12.6, increasing the
probability of channel opening by inducing the appearance
of long-lasting subconducting states. In this scheme, RyR2
hyperphosphorylation (up to 800% of control [37]) causes
the enhanced diastolic Ca
2+ leak. Unfortunately, this
mechanism remains controversial. Although a few studies
support some aspects of this mechanism, most groups
have not been able to reproduce the central tenets of this
hypothesis. Although Jiang et al. reported that PKA and
the drug JTV519 both decreased FKBP12.6 binding
to RyR2 [157], several other groups found that PKA
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FKBP12.6 nor substantially modified channel gating
[88,89,94,97,158,159]. Ai et al. [160] reported that RyR2-
S2808 phosphorylation was increased by approximately
50% in a rabbit model of HF; however, a direct test of
PKA phosphorylation of RyR2 in canine and human HF
yielded no difference compared with control, and a phos-
pho-antibody against RyR2-S2808 detected equal phos-
phorylation levels in control and HF samples [158,161].
More recently, a mouse with genetic ablation of the RyR2-
S2808 site (S2808A), supposedly stabilized in the closed
state by close association with FKBP12.6, displayed normal
b-adrenergic response and similar progression towards
heart failure compared with wild-type mice [88,159].
Finally, FKBP12.0 dissociati o no fR y R 1i sc o n s i s t e n t l y
reported to destabilize channel closure, but at least two
groups failed to detect effects of FKBP12.6 dissociation of
RyR2 [38,162]. Clearly, more studies are needed to resolve
these conflicting results and clarify the potential role of
FKBP12.6, SR Ca
2+ leak, and PKA phosphorylation of
RyR2-S2808 in HF.
Summary
In addition to providing the majority of the Ca
2+ necessary
for contraction of cardiac and skeletal muscle, RyRs act as
molecular switchboards that integrate a multitude of cyto-
solic signals such as dynamic and steady Ca
2+ fluctuations,
b-adrenergic stimulation (phosphorylation), nitrosylation
and metabolic states, and transduce these signals to the
channel pore to release appropriate amounts of Ca
2+.
Furthermore, because Ca
2+ release is crucially modulated
by luminal factors such as SR Ca
2+ content and protein-
protein interactions, RyRs play an additional role as inte-
grative switch-valves that offset cytosolic-luminal Ca
2+
imbalances. Thus, there is an ample margin to interfere
with the activity of RyRs. In both experimental and natural
conditions, such interference results in overt contractile
dysfunction and gross morphological changes. MH, CCD
and CPVT are among the most studied clinical presenta-
tions of RyR dysfunction, and the elucidation of the pre-
cise molecular mechanisms affected by this dysfunction is
advancing with great strides.
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